Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial

The Lancet Haematology - Tập 8 Số 3 - Trang e175-e184 - 2021
Tiziano Barbui1, Alessandro M. Vannucchi2, Valerio De Stefano3, Arianna Masciulli1, Alessandra Carobbio1, Alberto Ferrari1, Arianna Ghirardi1, Elena Rossi3, Fabio Ciceri4, Massimiliano Bonifacio5, Alessandra Iurlo6, Francesca Palandri7, Giulia Benevolo8, Fabrizio Pane9,10, Alessandra Ricco11, Giuseppe Carli12, Marianna Caramella13, Davide Rapezzi14, Caterina Musolino15, Sergio Siragusa16, Elisa Rumi17, Andrea Patriarca18, Nicola Cascavilla19, Barbara Mora20, Emma Cacciola21, Carmela Mannarelli2, Giuseppe Gaetano Loscocco2, Paola Guglielmelli2, Silvia Betti3, Francesca Lunghi4, Luigi Scaffidi5, Cristina Bucelli6, Nicola Vianelli7, Marta Bellini22, Maria Chiara Finazzi22, Gianni Tognoni23, Alessandro Rambaldi24,22
1FROM, Fondazione per la Ricerca Ospedale di Bergamo, Bergamo, Italy
2CRIMM, Azienda Ospedaliera Universitaria Careggi, Dipartimento Di Medicina Sperimentale E Clinica, Università Di Firenze, Florence, Italy
3Dipartimento di Scienze Radiologiche ed Ematologiche, Sezione di Ematologia, Università Cattolica del Sacro Cuore—Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
4Unità Operativa Di Ematologia E Trapianto Midollo Osseo, IRCCS Ospedale San Raffaele, Milan, Italy
5Department of Medicine, Section of Hematology, University of Verona, Policlinico Giambattista Rossi, Verona, Italy
6UOC Ematologia, Fondazione IRCCS Ca' Granda—Ospedale Maggiore Policlinico, Milan, Italy
7Institute of Hematology "L & A Seràgnoli", Azienda Ospedaliero—Universitaria di Bologna, Bologna, Italy
8SC Ematologia, AOU Città della Salute e della Scienza di Torino—Presidio Ospedaliero Molinette, Turin, Italy
9Dipartimento di Medicina clinica e Chirurgia, Università di Napoli Federico II, Napoli, Italy
10UOC di Ematologia e Trapianti di Midollo, Azienda Ospedaliera Universitaria Federico II di Napoli, Napoli, Italy
11U.O. Ematologia Con Trapianto Azienda Ospedaliera Universitaria “Consorziale Policlinico” Di Bari, Bari, Italy
12UOC Ematologia, Azienda ULSS 8 Berica Ospedale San Bortolo Di Vicenza, Vicenza, Italy
13Divisione Ematologia, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
14Divisione Di Ematologia, Azienda Ospedaliera S. Croce E Carle Di Cuneo, Cuneo, Italy
15UOC Ematologia, Azienda Ospedaliera Universitaria Policlinico “G Martino”, Messina, Italy
16Divisione Ematologia, Azienda Ospedaliera Universitaria Policlinico “P. Giaccone”, Palermo, Italy
17Divisione Di Ematologia, Fondazione IRCCS Policlinico San Matteo Pavia, Pavia, Italy
18SCDU Ematologia, Azienda Ospedaliero Universitaria Maggiore Della Carità, Novara, Italy
19UO Ematologia IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo, San Giovanni Rotondo, Italy
20Divisione UO Ematologia, ASST dei Sette Laghi, Varese, Italy
21UOC di Emostasi Centro Federato FCSA, Azienda Ospedaliera Universitaria "Policlinico Vittorio Emanuele" PO Gaspare Rodolico, Catania, Italy
22UOC Ematologia, ASST Papa Giovanni XXIII, Bergamo, Italy
23IRCCS – Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy
24Dipartimento di Oncologia ed Emato-oncologia, Università degli Studi di Milano, Milan, Italy.

Tóm tắt

Từ khóa


Tài liệu tham khảo

Tefferi, 2019, Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management, Am J Hematol, 94, 133, 10.1002/ajh.25303

Barbui, 2014, In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology, Blood, 124, 3021, 10.1182/blood-2014-07-591610

Landolfi, 2004, Efficacy and safety of low-dose aspirin in polycythemia vera, N Engl J Med, 350, 114, 10.1056/NEJMoa035572

Barbui, 2015, Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis, Am J Hematol, 90, 434, 10.1002/ajh.23970

Roncaglioni, 2013, N-3 fatty acids in patients with multiple cardiovascular risk factors, N Engl J Med, 368, 1800, 10.1056/NEJMoa1205409

Baigent, 2009, Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials, Lancet, 373, 1849, 10.1016/S0140-6736(09)60503-1

Marchioli, 2013, Cardiovascular events and intensity of treatment in polycythemia vera, N Engl J Med, 368, 22, 10.1056/NEJMoa1208500

Carobbio, 2019, Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis, Blood Adv, 3, 1729, 10.1182/bloodadvances.2019000211

Ronner, 2020, Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis, Blood, 135, 1696, 10.1182/blood.2019003347

Vannucchi, 2020, To be, or not to be, Blood, 135, 1617, 10.1182/blood.2020005363

Scherber, 2017, The potential role of hematocrit control on symptom burden among polycythemia vera patients: insights from the CYTO-PV and MPN-SAF patient cohorts, Leuk Lymphoma, 58, 1481, 10.1080/10428194.2016.1246733

Berk, 1986, Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols, Semin Hematol, 23, 132

Barbui, 2017, A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: a propensity-matched study, Am J Hematol, 92, 1131, 10.1002/ajh.24851

Barbui, 2018, Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European Leukemia Net, Leukemia, 32, 1057, 10.1038/s41375-018-0077-1

Mesa, 2017, NCCN guidelines insights: myeloproliferative neoplasms, version 2.2018, J Natl Compr Canc Netw, 15, 1193, 10.6004/jnccn.2017.0157

Kiladjian, 2016, Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone, Leukemia, 30, 776, 10.1038/leu.2015.326

Gisslinger, 2015, Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera, Blood, 126, 1762, 10.1182/blood-2015-04-637280

Gisslinger, 2020, Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study, Lancet Haematol, 7, e196, 10.1016/S2352-3026(19)30236-4

Emanuel, 2012, Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs, J Clin Oncol, 30, 4098, 10.1200/JCO.2012.42.3863

Barosi, 2013, Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project, Blood, 121, 4778, 10.1182/blood-2013-01-478891

Brannath, 2009, Exact confidence bounds following adaptive group sequential tests, Biometrics, 65, 539, 10.1111/j.1541-0420.2008.01101.x

Lan, 1983, Discrete sequential boundaries for clinical trials, Biometrika, 70, 659, 10.2307/2336502

Dimairo, 2020, The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design, BMJ, 369, m115, 10.1136/bmj.m115

Thông tin
Thông tin xuất bản

The Lancet Haematology

Tập 8 Số 3

e175-e184

Thông tin tác giả